Research Analysts Offer Predictions for CorMedix Q1 Earnings

CorMedix Inc (NASDAQ:CRMD) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for CorMedix in a research note issued on Friday, January 23rd. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.73 per share for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2030 earnings at $2.47 EPS.

A number of other brokerages have also recently issued reports on CRMD. Needham & Company LLC cut their price objective on CorMedix from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Wall Street Zen downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of CorMedix in a research report on Thursday, January 8th. Zacks Research lowered shares of CorMedix from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, D Boral Capital raised CorMedix from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, CorMedix presently has a consensus rating of “Buy” and a consensus target price of $15.86.

CorMedix Price Performance

CorMedix stock opened at $7.27 on Monday. The business has a 50 day simple moving average of $10.14 and a 200 day simple moving average of $11.22. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73. The company has a market capitalization of $572.80 million, a PE ratio of 3.53 and a beta of 1.36. CorMedix has a one year low of $5.60 and a one year high of $17.43.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings data on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The company had revenue of $104.28 million for the quarter, compared to the consensus estimate of $65.63 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The company’s quarterly revenue was up 810.2% on a year-over-year basis.

Institutional Investors Weigh In On CorMedix

Institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue increased its holdings in CorMedix by 951.5% in the fourth quarter. State of Alaska Department of Revenue now owns 49,358 shares of the company’s stock valued at $573,000 after purchasing an additional 44,664 shares during the last quarter. Phocas Financial Corp. acquired a new position in shares of CorMedix during the 4th quarter worth about $1,990,000. Palisades Investment Partners LLC increased its stake in shares of CorMedix by 2.2% in the 4th quarter. Palisades Investment Partners LLC now owns 576,759 shares of the company’s stock valued at $6,708,000 after acquiring an additional 12,653 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of CorMedix by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 30,245 shares of the company’s stock valued at $368,000 after acquiring an additional 2,646 shares during the period. Finally, Hennion & Walsh Asset Management Inc. bought a new position in CorMedix during the 4th quarter worth approximately $1,604,000. 34.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CorMedix

In related news, CEO Joseph Todisco sold 30,000 shares of CorMedix stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $12.00, for a total value of $360,000.00. Following the completion of the sale, the chief executive officer directly owned 509,496 shares in the company, valued at $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan W. Dunton sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total transaction of $260,000.00. Following the sale, the director directly owned 40,250 shares of the company’s stock, valued at approximately $523,250. This trade represents a 33.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 90,000 shares of company stock worth $1,095,200 over the last 90 days. 3.10% of the stock is owned by insiders.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.